These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24641389)

  • 1. Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.
    Zhang ZR; Duan YC
    Asian Pac J Cancer Prev; 2014; 15(4):1681-4. PubMed ID: 24641389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
    Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
    Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Skov V; Kjaer L; Hasselbalch HC; Ottesen JT
    Eur J Haematol; 2021 Dec; 107(6):624-633. PubMed ID: 34411333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
    Bai J; Xue YP; Zhang L; Li CH; Fan DM; Li B; Xu SC; Li DP; Sun XJ; Jiang B; Yang RC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera].
    Sokolova MA; Turkina AG; Melikian AL; Sudarikov AB; Treglazova SA; Shukhov OA; Gemdzhian EG; Abdullaev AО; Kovrigina AM; Misyurin AV; Pliskunova YV; Ivanova VL; Moiseeva TN
    Ter Arkh; 2016; 88(12):69-77. PubMed ID: 28139563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
    Quintás-Cardama A; Kantarjian H; Manshouri T; Luthra R; Estrov Z; Pierce S; Richie MA; Borthakur G; Konopleva M; Cortes J; Verstovsek S
    J Clin Oncol; 2009 Nov; 27(32):5418-24. PubMed ID: 19826111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.
    Pedersen RK; Andersen M; Knudsen TA; Sajid Z; Gudmand-Hoeyer J; Dam MJB; Skov V; Kjaer L; Ellervik C; Larsen TS; Hansen D; Pallisgaard N; Hasselbalch HC; Ottesen JT
    Cancer Med; 2020 Mar; 9(6):2039-2051. PubMed ID: 31991066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
    Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Papaemmanuil E; Salama M; Singer-Weinberg R; Rampal R; Goldberg JD; Barbui T; Mesa R; Dueck AC; Hoffman R
    Blood; 2019 Oct; 134(18):1498-1509. PubMed ID: 31515250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
    Quintás-Cardama A; Abdel-Wahab O; Manshouri T; Kilpivaara O; Cortes J; Roupie AL; Zhang SJ; Harris D; Estrov Z; Kantarjian H; Levine RL; Verstovsek S
    Blood; 2013 Aug; 122(6):893-901. PubMed ID: 23782935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
    Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
    Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
    Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
    Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
    Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
    Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
    Panova-Noeva M; Marchetti M; Buoro S; Russo L; Leuzzi A; Finazzi G; Rambaldi A; Ottomano C; Ten Cate H; Falanga A
    Blood; 2011 Sep; 118(9):2599-601. PubMed ID: 21750318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.